Iron isomaltoside/ferric derisomaltose

DRUG5 trials

Sponsors

Pharmacosmos A/S

Conditions

Chronic Kidney DiseaseIron Deficiency AnaemiaIron Deficiency Anemia

Phase 3

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

CompletedNCT02940860

Pharmacosmos A/SChronic Kidney Disease, Iron Deficiency Anaemia, Iron Deficiency Anemia

Start: 2016-11-29End: 2018-05-29Updated: 2020-10-06

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

CompletedNCT02940886

Pharmacosmos A/SIron Deficiency Anaemia, Iron Deficiency Anemia

Start: 2016-11-08End: 2018-03-28Updated: 2020-10-06

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

CompletedNCT02962648

Pharmacosmos A/SIron Deficiency Anaemia, Iron Deficiency Anemia

Start: 2017-01-09End: 2018-06-12Updated: 2020-03-10

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

CompletedNCT03237065

Pharmacosmos A/SIron Deficiency Anaemia, Iron Deficiency Anemia

Start: 2017-10-30End: 2018-05-29Updated: 2020-02-25

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

CompletedNCT03238911

Pharmacosmos A/SIron Deficiency Anaemia, Iron Deficiency Anemia

Start: 2017-10-24End: 2018-06-19Updated: 2020-02-25

Related Papers

Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia

JAMA2020-02-04257 citations